Research

Hormonal

Targeting specific inflammatory pathways (IL-1beta, NLRP3) reduces cardiovascular disease events in patients with obesity and elevated inflammation, independent of lipid-lowering effects.

If you have obesity and high inflammation markers (like CRP), your risk of heart disease is significantly driven by inflammation, not just cholesterol. While lifestyle changes are primary, emerging treatments targeting inflammation (like IL-1beta blockers) can reduce heart events by ~15% in high-risk groups, though they carry infection risks and do not fix blood sugar issues.

GoodSupportsHIGH confidence
The CANTOS trial evaluated the role of IL-1 beta antagonism on the incidence of T2D and CVD. CVD decreased by ~15% in patients with elevated hsCRP... These findings are scientifically important as they represent the first convincing evidence that a strategy that targets a specific inflammatory pathway reduces CVD.
Rana Khafagy et al. · Frontiers in Cardiovascular Medicine · 2021

Why this rating

Supported by large randomized control trials (CANTOS, LoDoCo2) and Mendelian randomization studies, though off-target effects (infection) limit broad application.

Source

Obesity and Cardiovascular Disease: The Emerging Role of Inflammation

Rana Khafagy et al. · Frontiers in Cardiovascular Medicine · 2021

DOI 10.3389/fcvm.2021.768119

narrative_reviewCited 58×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →